Coremed, Inc. - The industry leader in oral and inhaled insulin


	Nov 14: Coremed, Inc. introduces IVE™, a proprietary drug-delivery platform technology that improves protein absorption within the gastrointestinal tract > Read more
	Aug 24: Coremed, Inc. signs joint venture with China's major pharmas to develop Alveair™ inhalable insulin > Read more
	Jun 2: Coremed, Inc. to Raise Funds and Structure Strategic Alliances for Developing Inhalable and Oral Insulin-Delivery Systems > Read more
	Feb 6: Based on Pre-Clinical Data, Coremed, Inc.'s Alveair Insulin™ Achieves Better Insulin Bioavailability Than Intravenous Injection of Analog Insulin > Read more

Alveair™ is an inhaled insulin delivery system which has the potential to provide patients with diabetes a “needle-less” alternative to current insulin injections. The technology uses a generic hand-held device that delivers inhaled insulin with the same units as conventionally injected insulin, making it possible for the direct substitution of injectable insulin. > Read more

Coremed, Inc. is a privately funded biotech company founded in 1994. Coremed has developed an inhalable form of insulin based on a proprietary new platform for drug delivery. Our first product "Alveair", boasts close to 100% bio-availability, no respiratory side-effects during preliminary human trials, and oral delivery rendering injections unnecessary. Alveair has generated tremendous interest from major pharmaceutical companies and trade organizations, and is currently beginning Phase 1 clinical trials.
> Read more